HemaQuest is a San Diego and Seattle-based biopharmaceutical company developing proprietary small molecules targeting specific genes that enable the treatment of serious and life threatening hematologic disorders. Currently, the Company has one therapeutic in Phase 2 clinical development - HQK-1001 for sickle cell disease and beta thalassemia. The Company was founded in late 2007 by leading hematologists with funding from top tier investors, including De Novo Ventures, Forward Ventures, and Lilly Ventures. In 2010 they were joined by additional investors, Aberdare Ventures and Latterell Venture Partners.

Technology Overview

HemaQuest's Founders discovered that short chain fatty acids (SCFA) possess a variety of important biological effects of therapeutic benefit in treating patients with a range of hematologic disorders. Learn More...

Hemoglobin Disorders

At present, there are limited therapeutic options available for patients suffering from sickle cell disease and beta thalassemia. HemaQuest is developing new therapies for these chronic and debilitating illnesses. Learn More...